Celcuity Inc., a cellular analysis company, discovers cancer sub-types and commercializes diagnostic tests to enhance the response rates of cancer patients treated with targeted therapies in the United States. The company is developing CELx tests to diagnose two new sub-types of HER2-negative breast cancer. It is also developing CELx tests to diagnose 14 new potential cancer sub-types in breast, lung, colon, ovarian, kidney, bladder, and hematological cancers. The company was founded in 2012 and is headquartered in Minneapolis, Minnesota. The company trades on NASDAQ exchange. The company headquarter is located in Minneapolis, MN. The company was established in the 2012.

TickerCELC
Long NameCelcuity Inc.
Short NameCelcuity